Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.59 |
| ▸ | CKS1B | P61024 | 1/20 | 0.57 |
| ▸ | SKP1 | P63208 | 1/20 | 0.57 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347348 | 0.85 | KDM4E (0.63) | KDM4ECKS1BSKP1SKP2GPR119 | |
| SCHEMBL19652126 | 0.82 | CKS1B (0.63) | KDM4ECKS1BSKP1SKP2GPR119 | |
| SCHEMBL19652097 | 0.78 | MEN1 (0.55) | KDM4ECKS1BSKP1SKP2GPR119 | |
| SCHEMBL8693976 | 0.77 | KDM4E (0.58) | KDM4EGPR119RXFP1TP53L3MBTL1 | |
| SCHEMBL18228085 | 0.77 | GPR119 (0.58) | KDM4ECKS1BSKP1SKP2GPR119 | |
| SCHEMBL18228358 | 0.77 | GPR119 (0.58) | KDM4ECKS1BSKP1SKP2GPR119 | |
| SCHEMBL19652166 | 0.75 | CKS1B (0.56) | CKS1BSKP1SKP2ALDH1A1GAA | |
| SCHEMBL19652105 | 0.75 | KDM4E (0.54) | KDM4EGPR119RXFP1TP53L3MBTL1 | |
| SCHEMBL19652157 | 0.75 | CKS1B (0.52) | CKS1BSKP1SKP2ALDH1A1GAA | |
| SCHEMBL12639920 | 0.75 | KDM4E (0.72) | KDM4EGPR119RXFP1TP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | KDM4E 320/4885CKS1B 239/4885SKP1 2240/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | KDM4E 320/4885CKS1B 239/4885SKP1 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.